Histopathologic and genetic distinction of well-differentiated grade 3 neuroendocrine tumor versus poorly-differentiated neuroendocrine carcinoma in high-grade neuroendocrine neoplasms

Online journal article in Molecular Pathology that offers 1.0 continuing education (CME) credit that can be used to fulfill CC Part II requirements.

Quantity:

Want to save more?

Log into see if you qualify for a lower rate.

Members

save $6.00 or more

Intended Audience: Pathologists, Residents, Clinical Scientists, Pathologist Assistants

Upon completion of this activity, you will be able to:

Summarize the key points in the 2022 World Health Organization (WHO) Classification of Endocrine and Neuroendocrine Tumors (NETs) regarding grade 3 NETs...

Intended Audience: Pathologists, Residents, Clinical Scientists, Pathologist Assistants

Upon completion of this activity, you will be able to:

Summarize the key points in the 2022 World Health Organization (WHO) Classification of Endocrine and Neuroendocrine Tumors (NETs) regarding grade 3 NETs and poorly-differentiated neuroendocrine carcinoma (NEC).

List the histological and immunohistochemical differences between Grade 3 Neuroendocrine Tumor (G3-NET) and NEC and any relevant potential overlapping features that may lead to diagnostic challenges.

Discuss genetic differences between G3-NETs and NECs, including gene mutations and associated functional pathways, including how these may be related to site-specific origin.

View More View Less